Recent FDA approvals (through January 2010) related to Cymbalta, Zyprexa, Zyprexa Relprevv, Intelence, Kalbitor, Istodax, Geodon, Vagifem, Seroquel XR, Clonidine ER Suspension, Clonidine ER Tablets, Wilate
Duloxetine HCl (Cymbalta, Eli Lilly) was approved for the maintenance treatment of generalized anxiety disorder in adults.
Olanzapine (Zyprexa, Eli Lilly) was approved as treatment for schizophrenia and bipolar disorder in teenagers.
Olanzapine extended release injectable suspension (Zyprexa Relprevv, Eli Lilly) was approved for the treatment of schizophrenia in adults.
Ecallantide (Kalbitor, Dyax) was approved for treatment of hereditary angioedema in patients 16 years and older.
Romidepsin (Istodax, Gloucester Pharmaceuticals) was approved for the treatment of cutaneous T-cell lymphoma in patients who have received at least one prior systemic therapy.
Ziprasidone (Geodon, Pfizer) was approved for maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate.
Estradiol vaginal tablets, 10 µg dose formulation (Vagifem, Novo Nordisk) for the treatment of atrophic vaginitis due to menopause.
Quetiapine fumarate extended-release tablets (Seroquel XR, AstraZeneca) as an add-on for antidepressants used by adults with major depressive disorder.
Direct-acting alpha 2 adrenergic agonists in two different strengths (once-daily Clonidine ER Suspension and once-daily Clonidine ER Tablets, Tris Pharma) were approved for treatment of hypertension.
Double virus inactivated von Willebrand factor/coagulation factor VIII concentrate, human (Wilate, Octapharma USA), was approved for the treatment of spontaneous and trauma-induced bleeding episodes in patients with all types of von Willebrand disease.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
Iowa Expands PBM Legislation to Address Concerns of Independent Pharmacies
May 16th 2025A new law in Iowa, if signed by the governor, will mandate 100% pass-through of rebates, increased financial transparency, and a minimal payment for pharmacies. Critics say it will be the most costly mandate in the state’s history.
Read More
Is Arkansas’ New PBM Law the Right Path Forward for Reform? No One Knows Yet
May 9th 2025It could improve access to community pharmacies and lower prices. Or it will limit access to critical drugs and impact payers’ ability to contract for a broad range of services. Industry leaders are unsure about the impact of Arkansas’ law banning PBMs from owning pharmacies.
Read More